Literature DB >> 18074121

In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.

Shuji Maruyama1, Naoki Hasuike, Kazuhiro Suzuki, Shizuo Yamada.   

Abstract

The present study was undertaken to characterize in vivo muscarinic receptors in peripheral tissues (urinary bladder, submaxillary gland, colon, stomach, heart) of mice, and further to evaluate bladder-selectivity of anticholinergic agents to treat overactive bladder. Following i.v. injection of [3H]QNB in mice, the radioactivity in peripheral tissues was exclusively detected as the unchanged form. The in vivo specific [3H]QNB binding in particulate fraction of tissue homogenates of mice showed a pharmacological specificity which characterized muscarinic receptors. Binding parameters (Kd and Bmax) for in vivo specific [3H]QNB binding differed between mouse tissues. Oral administration of oxybutynin attenuated significantly in vivo specific [3H]QNB binding in all tissues of mice. From ratios of AUCurinary bladder/AUCother tissues of time-dependent muscarinic receptor occupancy, oral oxybutynin has been shown to exert little urinary bladder selectivity. Following oral administration of propiverine, there was a significant reduction of in vivo specific [3H]QNB binding in the urinary bladder, colon and submaxillary gland, but not in the stomach and heart. From the ratios of AUCurinary bladder to AUCsubmaxillary gland or AUCheart, it has been shown that oral propiverine exerts higher selectivity to muscarinic receptors in the urinary bladder than in the submaxillary gland and heart. Similarly, tolterodine displayed high selectivity to muscarinic receptors in the urinary bladder than in the submaxillary gland. Thus, the present study has demonstrated that [3H]QNB may be a useful ligand for in vivo characterization of muscarinic receptor binding of anticholinergic agents to treat overactive bladder. Propiverine and tolterodine have exhibited in vivo selectivity of muscarinic receptor in the mouse urinary bladder rather than in the submaxillary gland, and such receptor binding specificity may be the reason of lower incidence of dry mouth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18074121     DOI: 10.1007/s00210-007-0207-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.

Authors:  A Todorova; B Vonderheid-Guth; W Dimpfel
Journal:  J Clin Pharmacol       Date:  2001-06       Impact factor: 3.126

2.  In vivo identification of muscarinic cholinergic receptor binding in rat brain.

Authors:  H I Yamamura; M J Kuhar; S H Snyder
Journal:  Brain Res       Date:  1974-11-08       Impact factor: 3.252

3.  Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain.

Authors:  R Hosoi; K Kobayashi; Y Watanabe; O Inoue
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

4.  Effects of the anticholinergic drug prifinium bromide on urinary bladder contractions in rat in vivo and in guinea-pig in vitro.

Authors:  T Terai; Y Deguchi; M Ohtsuka; S Kumada
Journal:  Arzneimittelforschung       Date:  1991-04

5.  In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.

Authors:  Shizuo Yamada; Shuji Maruyama; Yukiko Takagi; Shinya Uchida; Tomomi Oki
Journal:  Life Sci       Date:  2006-09-01       Impact factor: 5.037

6.  Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice.

Authors:  I Påhlman; R d'Argy; L Nilvebrant
Journal:  Arzneimittelforschung       Date:  2001-02

7.  A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.

Authors:  H Madersbacher; M Halaska; R Voigt; S Alloussi; K Höfner
Journal:  BJU Int       Date:  1999-10       Impact factor: 5.588

8.  [Effects of oxybutynin hydrochloride on the urinary bladder and urethra in in situ preparations].

Authors:  K Mayuzumi; K Watanabe; K Tamaru; T Kasama
Journal:  Nihon Yakurigaku Zasshi       Date:  1986-05

9.  Identification of direct competition for, and indirect influences on, striatal muscarinic cholinergic receptors: in vivo [3H]quinuclidinyl benzilate binding in rats.

Authors:  R W Pelham; T L Munsat
Journal:  Brain Res       Date:  1979-08-10       Impact factor: 3.252

10.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06
View more
  3 in total

Review 1.  α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

Authors:  Shizuo Yamada; Yoshihiko Ito; Hideo Tsukada
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

2.  Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.

Authors:  Adil E Bharucha; Karthik Ravi; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-15       Impact factor: 4.052

3.  Experience with imidafenacin in the management of overactive bladder disorder.

Authors:  Takumi Takeuchi; Masayoshi Zaitsu; Koji Mikami
Journal:  Ther Adv Urol       Date:  2013-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.